Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach

Publisher Website
Google Scholar
Abstract
The role of cannabinoid (CB) receptors in the regulation of gastric acid secretion was investigated in the rat by means of functional experiments and by immunohistochemistry. In anaesthetized rats with lumen‐perfused stomach, the non selective CB‐receptor agonist WIN 55,212‐2 (0.30 – 4.00 μmol kg−1, i.v.) and the selective CB1‐receptor agonist HU‐210 (0.03 – 1.50 μmol kg−1, i.v.), dose‐dependently decreased the acid secretion induced by both pentagastrin (30 nmol kg−1 h−1) and 2‐deoxy‐D‐glucose (1.25 mmol kg−1, i.v.). By contrast, neither WIN 55,212‐2 (1 – 4 μmol kg−1, i.v.) nor HU‐210 (0.03 – 1.50 μmol kg−1, i.v.) did modify histamine‐induced acid secretion (20 μmol kg−1 h−1). The selective CB2‐receptor agonist JWH‐015 (3 – 10 μmol kg−1, i.v.) was ineffective. The gastric antisecretory effects of WIN 55,212‐2 and HU‐210 on pentagastrin‐induced acid secretion were prevented by the selective CB1‐receptor antagonist SR141716A (0.65 μmol kg−1, i.v.) and unaffected by the selective CB2‐receptor antagonist SR144528 (0.65 – 2 μmol kg−1, i.v.). Bilateral cervical vagotomy and ganglionic blockade with hexamethonium (10 mg kg−1, i.v., followed by continuous infusion of 10 mg kg−1 h−1) significantly reduced, but not abolished, the maximal inhibitory effect of HU‐210 (0.3 μmol kg−1, i.v.) on pentagastrin‐induced acid secretion; by contrast, pretreatment with atropine (1 mg kg−1, i.v.) did not modify the antisecretory effect of HU‐210. Immunoreactivity to the CB1 receptor was co‐localized with that of the cholinergic marker choline acetyltransferase in neural elements innervating smooth muscle, mucosa and submucosal blood vessels of rat stomach fundus, corpus and antrum. In contrast, CB2 receptor‐like immunoreactivity was not observed. These results indicate that gastric antisecretory effects of cannabinoids in the rat are mediated by suppression of vagal drive to the stomach through activation of CB1 receptors, located on pre‐ and postganglionic cholinergic pathways. However, the ineffectiveness of atropine in reducing the effect of HU‐210 suggests that the release of non cholinergic excitatory neurotransmitters may be regulated by CB1 receptors. British Journal of Pharmacology (2002) 135, 1598–1606; doi:10.1038/sj.bjp.0704625